Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status
Abstract As a kind of gynecological tumor, ovarian cancer is not as common as cervical cancer and breast cancer, but its malignant degree is higher. Despite the increasingly mature treatment of ovarian cancer, the five-year survival rate of patients is still less than 50%. Based on the concept of sy...
Saved in:
Main Authors: | Yongsong Wu (Author), Shilin Xu (Author), Shanshan Cheng (Author), Jiani Yang (Author), Yu Wang (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2023-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A novel autophagy-related gene signature associated with prognosis and immune microenvironment in ovarian cancer
by: Jiani Yang, et al.
Published: (2023) -
Integration of PARP-inhibitors in ovarian cancer therapy
by: Antonella Pietragalla, et al.
Published: (2020) -
The Current State of the Art in PARP Inhibitor-Based Delivery Nanosystems
by: Lisha Cai, et al.
Published: (2022) -
Poly(ADP-ribose) polymerase (PARP) inhibitors and ovarian cancer
by: Chia-Hao Liu, et al.
Published: (2017) -
Prior authorization for FDA-approved PARP inhibitors in ovarian cancer
by: Anna Jo Bodurtha Smith, et al.
Published: (2024)